surmount-1 tirzepatide weight loss nondiabetic Achieving BMI <25 kg/m2 was associated with reduced predicted risk of atherosclerotic cardiovascular disease in people with obesity or overweight on or placebo: a post hoc analysis of SURMOUNT-1, -3, and Tirzepatide for Obesity: Highlights from

While the 2025 Employer Health Benefit Survey finds there was a notable increase in the share of the largest firms (5,000+) that cover GLP-1 medications for weight loss, the conversations with employers highlight their concerns about the cost of these medications

Lyophilization removes water under low temperature and vacuum, which helps preserve peptide stability during storage

"En el sistema nervioso central, el GLP-1 tambin reduce ese deseo, esa ansiedad por comer productos grasos o ricos en carbohidratos", explica el neurlogo Sandro Matas, coordinador del servicio de Neurologa de la unidad de Pompeia del Hospital So Camilo

The brand offers live chat Monday through Friday, 8AM-5PM Central Time